Source comparison
Effectiveness Comparison
Clinical efficacy data for sermorelin comes primarily from pediatric growth hormone deficiency trials and adult anti-aging studies. The landmark study by Thorner et al. demonstrated that sermorelin 1-2 mcg/kg subcutaneously increased mean 24-hour growth hormon
This comparison does not assign a generated winner or score.
- Clinical efficacy data for sermorelin comes primarily from pediatric growth hormone deficiency trials and adult anti-aging studies. The landmark study by Thorner et al. demonstrated that sermorelin 1-2 mcg/kg subcutaneously increased mean 24-hour growth hormone levels by 42% and IGF-1 concentrations by 35% in healthy adults aged 45-65[19]. A subsequent 6-month trial in 65 adults with age-related growth hormone decline showed sermorelin therapy resulted in 28% improvement in lean body mass and 15% reduction in visceral adipose tissue compared to placebo[20].
- CJC-1295/Ipamorelin combination therapy data comes from smaller investigational studies and retrospective clinic analyses. Walker et al. reported that CJC-1295 100 mcg plus ipamorelin 100 mcg administered three times weekly increased mean growth hormone AUC by 78% and IGF-1 levels by 65% in 32 adults over 12 weeks[21]. A retrospective analysis of 156 patients receiving combination therapy at anti-aging clinics showed average body fat reduction of 12% and lean mass increase of 8% over 6 months[22]. However, these studies lack the rigorous design and sample sizes of FDA-regulated trials.
- IGF-1 Increase
- 35-50%
- 60-80%
- GH AUC Improvement
- 40-45%
- 70-85%
- Lean Mass Gain
- 2-4% (6 months)
- 6-8% (6 months)
- Fat Mass Reduction
- 8-15%
- 10-15%
- Study Quality
- FDA-regulated trials
- Investigational/retrospective
- Sample Sizes
- 50-200 participants
- 15-50 participants
- Direct head-to-head comparison studies between sermorelin and CJC-1295/Ipamorelin are notably absent from the literature, limiting definitive efficacy conclusions[23]. The available data suggests potentially greater growth hormone stimulation with combination therapy, but this comes with increased regulatory uncertainty and cost.